Proportion of Tubal Factor Infertility due to Chlamydia:finite mixture modeling of serum antibody titers by Ades, AE et al.
 
 
Proportion of Tubal Factor Infertility due to
Chlamydia
Ades, AE; Price, Malcolm; Kounali, D.; Akande, V.A.; Wills, G.S.; McClure, M.O.; Muir, P.;
Horner, PJ
DOI:
10.1093/aje/kww117
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Ades, AE, Price, M, Kounali, D, Akande, VA, Wills, GS, McClure, MO, Muir, P & Horner, PJ 2017, 'Proportion of
Tubal Factor Infertility due to Chlamydia: finite mixture modeling of serum antibody titers', American Journal of
Epidemiology, vol. 185, no. 2, pp. 124–134. https://doi.org/10.1093/aje/kww117
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
This is a pre-copyedited, author-produced PDF of an article accepted for publication in American Journal of Epidemiology following peer
review. The version of recordA. E. Ades, M. J. Price, D. Kounali, V. A. Akande, G. S. Wills, M. O. McClure, P. Muir, P. J. Horner; Proportion
of Tubal Factor Infertility due to Chlamydia: Finite Mixture Modeling of Serum Antibody Titers, American Journal of Epidemiology, Volume
185, Issue 2, 15 January 2017, Pages 124–134, https://doi.org/10.1093/aje/kww117 is available online at: 10.1093/aje/kww117
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
1 
 
Proportion of Tubal Factor Infertility due to Chlamydia: finite mixture modeling of serum 
antibody titers. 
AE* Ades, MJ. Price, D. Kounali, VA. Akande, GS. Wills, MO. McClure, P. Muir,  
PJ. Horner 
(*) Correspondence to: Professor AE Ades; School of Social and Community Medicine, 39 
Whatley Road, Bristol BS8 2PS, United Kingdom. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 
 
Abstract 
This study examined whether the proportion of Tubal Factor Infertility (TFI) that is attributable 
to Chlamydia trachomatis, the population excess fraction (PEF), can be estimated from 
serological data using finite mixture modeling. Whole cell inclusion immune-fluorescence   
serum antibody titers were recorded in infertile women who were seen at St. Michael’s 
Hospital, Bristol, between 1985-1995 and classified as TFI cases or controls based on 
laparoscopic examination. Finite mixture models were used to identify the number of 
component titer distributions and the proportion of samples in each, from which estimates of 
PEF were derived. Four titer distributions were identified. The component at the highest titer 
was found only in samples from women with TFI, but there was also an excess of the second 
highest titer component in TFI cases. Minimum and maximum estimates of the PEF were 28.0% 
(95% credible interval: 6.9, 50.0) and 46.8% (95% Credible interval: 23.2, 64.1).  Equivalent 
estimates based on the standard PEF formula from case-control studies were 0% and over 65%. 
Finite mixture modeling can be applied to serological data to obtain estimates of the proportion 
of reproductive damage attributable to Chlamydia trachomatis. Further studies should be 
undertaken using modern assays in contemporary, representative populations. 
<198 words> 
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List of abbreviations 
CT  Chlamydia Trachomatis 
CT+  CT infected 
CT-  Not CT infected 
PID  Pelvic Inflammatory Disease 
WIF  Whole cell inclusion immune-fluorescence 
PEF  Population excess fraction 
TFI  Tubal factor fnfertility 
OR  Odds ratio 
CrI  Credible interval 
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Chlamydia Trachomatis (CT) is a common sexually transmitted infection of young people which 
if left untreated will cause pelvic inflammatory disease (PID) in around 16% of women (1). PID 
may then result in adverse reproductive outcomes such as ectopic pregnancy (EP) or tubal 
factor infertility (TFI) (2). In spite of research using a wide range of study designs, the precise 
quantitative relationship between Chlamydia trachomatis (CT) and reproductive damage 
remains elusive (2-4). CT, with or without the development of disease, usually resolves 
spontaneously. Diagnosed infection is treated, so prospective study of untreated infection is 
not feasible. The major studies of reproductive outcomes in women with PID (5-7) have been 
restricted to the small proportion of PID (8) that is diagnosed in hospital. In the 1980s and 
1990s large numbers of serological case-control studies were carried out, comparing serum 
antibody levels in women with PID, EP or infertility, with controls (9-19). These studies 
invariably showed strong associations between detection of CT antibodies and reproductive 
damage, but it was difficult to draw quantitative conclusions from them, partly because of 
confounding between CT and other pathogens also implicated in reproductive morbidity (20), 
and partly because of the poor, and imprecisely known, sensitivity and specificity of the assays 
used (21, 22). 
In this paper we adopt a new analytic approach to this problem: finite mixture modeling (23). 
Finite mixture models are used when a distribution, in this case of serum antibody titers, is 
considered to be a mixture of several components, for example “positives” and “negatives”, 
and where there is an interest in estimating  the proportion of samples in diseased and healthy 
populations in each component. Finite mixture models are often applied to diagnostic tests 
which lack a “gold standard”, including to serological data (24-28). 
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In this paper we apply finite mixture models to a previously published dataset (29). Whole cell 
inclusion immune-fluorescence (WIF) serum antibody titers were recorded in infertile women 
classified as having Tubal Factor Infertility (cases) or not (controls) following laparoscopy (Table 
1). Note that among the cases, a high proportion of the titers that would normally be 
considered positive (1:32 and above) are at particularly high levels. This has been observed 
repeatedly in similar studies of TFI (11, 15, 16, 30, 31), and PID (10, 18). In other words, women 
at higher risk of reproductive damage are more likely to be CT antibody positive, and are more 
likely to have particularly high titers than antibody-positive controls.  
The Lund studies (5-7) established that clinically diagnosed PID was only associated with 
reproductive damage in women with laparoscopically confirmed salpingitis. Our analysis, 
therefore, is premised on the assumption that the exceptionally high positive titers seen in TFI 
cases reflect an inflammatory reaction to CT that is associated with CT-related salpingitis, and 
that women with titers at these high levels are at risk of CT-related TFI (32). The purpose of the 
finite mixture analysis is to determine what proportion of the TFI cases have titers at these high 
levels. 
The estimates of the population excess fraction (PEF) formed in this way will be of substantive 
interest in the many countries where chlamydia and prevention control strategies are in 
operation, or being considered. However, in view of the limitations inherent in using data 
collected many years ago for another purpose, this paper should be seen in part as an 
exploratory, hypothesis forming, exercise into how and whether finite mixture modeling of 
anti-CT titers can contribute to an understanding of the role of CT in reproductive damage.  
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METHODS 
Data  
The primary dataset consisted of WIF titers from 434 TFI cases confirmed on laparoscopy, and 
573 controls who were infertile for other reasons, seen in a Reproductive Medicine Clinic, at St. 
Michael’s hospital in Bristol, between 1985 and 1995.  The data were collected in a study 
exploring the relationship between serum chlamydia antibody titers and detection of tubal 
damage in infertile women as previously reported (29) (Table 1). Titers of 1:32 or greater would 
normally be considered positive for CT antibody. Cases had a mean age of 29.3 years (range 18-
46) and controls 30.6 years (range 19-47). 
A proportion of low titer positives on WIF are likely to be cross-reactions to Chlamydia 
pneumonia (CP) in women with no exposure to CT (33) . A secondary dataset provided 
additional information on the proportion of CT negatives at each WIF titer. Anonymized 
samples from women undergoing investigation for infertility during 2013 were submitted to 
Bristol Public Health Laboratories and tested by WIF at Bristol Public Health Laboratories and by 
the highly specific Pgp3 CT antibody assay (33) at Imperial College.  The analyses reported here 
concern samples from 301 women with WIF titers at or below 1:1024. Causes of infertility and 
reproductive outcomes were not recorded.  
Models 
Three models were examined, each characterized by the number of latent distributions 
assumed to be present (Table 2). For example, the “2-3” model assumed that the control 
samples were a mixture of two distributions, which we label CT- (never infected) and CT+ 
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(previously infected no inflammatory response), while TFI samples may come from either of 
these distributions or from a third distribution, CT++, who have had an inflammatory response 
to CT infection. 
Further models were developed when it was found that the “2-3” model did not fit the data. In 
the “3-3” model a proportion of control samples is also allowed to belong to the CT++ 
distribution.  In the “3-4” model, a further distribution is proposed, CT+++, but only TFI samples 
may belong to it. These labels should be thought of simply as mnemonics, although as the 
labels suggest, they are listed in order of increasing titer with CT- lowest and representing true 
CT antibody negatives, and CT+++ the highest representing exceptionally high levels of serum 
antibody. 
Statistical methods 
Finite Mixture Modeling assumes that each distribution G of titers y is a mixture of say, D 
underlying latent distributions ( )df y , which we assume are Normal on the log titer scale. We 
further assume that the only difference between cases (k=1) and controls (k=0) is in the 
proportions of samples from each of the latent component distributions, d=1,…,D.            
𝐺𝐺𝑘𝑘(𝑦𝑦) = 𝜋𝜋𝑘𝑘1𝑓𝑓1(𝑦𝑦) + 𝜋𝜋𝑘𝑘2𝑓𝑓2(𝑦𝑦) + ⋯+ 𝜋𝜋𝑘𝑘𝑘𝑘𝑓𝑓𝑘𝑘(𝑦𝑦) 
The proportions kdπ   are the proportion of samples that can be attributed to latent 
distribution d, conditional on case / control status k. The means and standard deviations of the 
component distributions remain the same in cases and controls. 
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Although  titers are reported in categories, they are in fact censored observations on a 
continuous variable. If we designate  the lower boundary of categories {<1:64, 1:64, 1:128, 
1:256, 1:512, 1:1024, 1:2028, 1:4096, >1:4096} as: LOi ={-∞ ,1,2,3,4,5,6,7,8}, and the upper 
boundaries as HIi ={1,2,3,4,5,6,7,8,9, ∞ }, we can express the proportion of distribution d that 
falls into the ith category as: 
                             ( )
HI
LO
i
di di
f y dyθ = ∫                                                                                   
with y on the natural log titer scale. Finally, the proportions of samples, kiα ,  in each titer 
category i in group k  is obtained as the inner product of the diθ and the kdπ  : 
                             ki kd di
d
α π θ=∑         
The observed data is the number of samples kir  in each titer category i in TFI cases (k =1) and 
controls (k=0); this is multi-nomially distributed, with denominators nk :     
                              , 1...9 ,1...9~ ( , )k i k kr Multinomial nα=  
This multinomial distribution is the appropriate choice for the observables i.e. n trials (samples) 
with k possible outcomes (titers) on each trial, and a fixed probability of each outcome over all 
the trials.  
The secondary data source provides additional information on the proportion of true antibody 
negatives at each WIF titer (Table 1). This was based on the pgp-3 assay, which we assume to 
be effectively 100% specific (33). The data in Table 1 provides direct information on the 
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probability kiω  of a sample being in the CT- group, conditional on its titer and case / control 
status. This, in turn, constitute indirect information on 1iθ , the probability of a sample having a 
specified titer, given that it is CT-. We can use Bayes Rule to relate the quantities, with the index 
“1” indicating the CT- distribution: 
                   1 1i kki
di kd
d
θ π
ω
θ π
=
∑
 
 Because we do not know the proportion of TFI cases in the secondary dataset, we further 
define a weighted average of 1iω  for cases and 0iω  for controls, with the proportion which are 
cases 
TFIp to be estimated from the data: 
                          1 11 1 01.
1 0
(1 )TFI TFIi ii
di d di d
d d
p pθ π θ πω
θ π θ π
= + −
∑ ∑
 
The secondary data ir    providing information on the .iω  represent the numbers of pgp-3 
negatives among the sample in  with WIF titre i (Table 1). These have a Binomial likelihood:  
                           .~ ( , ),   1, 2....6i i ir Bin n iω =  
The secondary data covers only the first 6 titer categories, as there are no further pgp-3 
negatives in higher WIF categories (Table 1).Estimation. We adopt a Bayesian approach and 
proceed with computations using Markov Chain Monte Carlo (MCMC), supplying weak or non-
informative priors for dµ , kdπ , and weakly informative priors for the standard deviation 
parameters dσ . Mixture models can be unstable, and technical details of priors and constraints 
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adopted to achieve stability are supplied in the Web Appendix 1 along with WinBUGS code and 
datasets. Prior specifications are detailed in Web Appendix 2.  A series of sensitivity analyses 
were conducted testing robustness to changes in priors and structural assumptions: these are 
also described in the Web Appendix 3. Deviance statistics (34) , and comparison of observed 
and predicted counts at each WIF titer, were used to assess model fit and guide model 
selection. In a Bayesian MCMC framework the residual deviance (35) is calculated on each 
iteration. The posterior mean residual deviance is a global measure of goodness of fit, and is 
expected to be close to the number of observations if the model fits well. A reduction in 
residual deviance of 3 to 5 points is generally taken as evidence of a better fitting model. 
Convergence was achieved within 10,000-15,000 iterations using Brooks Gelman statistics (36). 
Posterior results are based on a total 120,000 samples from four chains, having discarded the 
first 30,000. 
Estimates of population excess fraction. In the “2-3” model the distribution with the highest 
mean titer is only found in the TFI cases. The proportion of TFI samples in the CT++ distribution 
in the “2-3” model is therefore a direct estimate of the PEF 
                                           2 3 1,CTPEF π
−
++=  
In the “3-3” model, a more complicated situation arises: here an estimate of the PEF can be 
based on the excess proportion of samples in the highest CT++ category in TFI cases compared 
to controls. Thus, it is necessary to take into account that a proportion of the CT++ observed in 
the TFI cases would occur anyway, even if TFI status was unrelated to antibody level. Consider 
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the number of CT++ samples observed in controls, as a proportion of all CT+ and CT++in the 
controls.  If there was no excess CT++ in the TFI cases we would expect 1,   CTπ ++ to equal:       
                                 
0,
1, 1,
0, 0,
( ) CTCT CT
CT CT
π
π π
π π
++
+ ++
+ ++
 
+   + 
 
The estimate of the PEF is the excess CT++ in the TFI group, which is therefore the difference 
between the observed CT++ in cases, and what we would predict from the controls: 
                       
0,3 3
1, 1, 1,
0, 0,
( ) CTCT CT CT
CT CT
PEF
π
π π π
π π
++−
++ + ++
+ ++
 
= − +   + 
 
For the “3-4” model, we can first follow the same logic as the “2-3” model. The proportion of 
cases in the CT+++ group is a direct estimate of the PEF: 3 4(1) 1,CTPEF π
−
+++= . This must be 
considered as a lower bound estimate because it ignores the excess proportion of CT++ 
observed in TFI cases. 
Acknowledging an excess in CT++ samples in TFI cases, in addition to the CT+++, we can follow 
the same argument set out for the “3-3” model. This leads to a second estimate of the PEF for 
“3-4” model, in which we add the proportion in CT+++ to the excess fraction of the CT++: 
                 
0,3 4(2)
1, 1, 1, 1,
0, 0,
( ) CTCT CT CT CT
CT CT
PEF
π
π π π π
π π
++−
+++ ++ + ++
+ ++
 
= + − +   + 
 
This can be considered as an upper bound estimate as it ascribes all the excess of CT++ in cases 
to a causal effect of CT infection. The equations for each estimate are presented in Table 2. The 
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extent to which these different estimates are vulnerable to confounding is taken up in the 
discussion. 
Results 
Model selection 
Table 3 compares the predicted titer distributions from each model with the observed data, 
and shows the goodness of fit (Residual Deviance) at each point. Systematic error is evident in 
the “2-3” and “3-3” models, in that they under-estimate the peak that can be seen in both 
control and TFI samples at 1:1024, while over-estimating the number of samples at 1:512. The 
“3-4” models on the other hand fit the distribution well at every point.   
The fit of models to data is elaborated further in Figure 1 – Figure 4. These plots, depict the 
fitted component distributions (in color), for each model and separately for cases and controls 
and are drawn to the correct scale in order to reflect the fitted proportions of each component. 
The predicted overall titer distribution (solid black line) is the sum of the components, and can 
be compared to the observed data shown as a histogram. 
In a good fitting model the residual deviance should be no more than the number of data 
points, which is 8 each in the cases and controls. Therefore the global residual deviance 
statistics at the foot of Table 3 rule out “2-3” and “3-3” models decisively, with the 3-4 models 
as an excellent fit.  
Parameter estimates and PEF 
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The estimated mean and standard deviation of the each of the log titer distributions, CT-, CT+, 
CT++, CT+++, are set out in Table 4, along with the proportions of cases and controls in each 
group. The introduction of a CT++ distribution for the controls in “3-3” and “3-4” models has 
the effect of lowering the mean of the CT+ distribution by about 1 log unit, and somewhat 
lowering its variance. Similarly, the introduction of a CT+++ category lowers the mean of the 
CT++ group and also reduces its variance. 
The secondary data source provides more information on the CT- distribution: the mean is 
raised to a somewhat higher titer, and the variance is reduced. Its main effect is to reduce 
uncertainty in the means and SDs of the CT- and CT+ distributions. The model fits the secondary 
data well, with a residual deviance of 4.0 on 6 observations, 2 of which were zeros.  
The central estimates of the PEF (Table 4) lie within the range 28%-48%. Although estimates 
from the “2-3” model can be discounted due its poor fit, it is interesting that it estimates almost 
exactly the same PEF as the upper bound estimate from the “3-4” model without secondary 
data. This shows that when the excess cases in the CT++ group are assumed to cause TFI one 
obtains very similar results whether or not one distinguishes between CT++ and CT+++ 
distributions.   
The secondary data has a slight impact on the estimates of PEF, lowering them by about 4 
percentage points. As expected, the probability that a sample in the secondary dataset was 
from a TFI and not a control was poorly estimated, 0.54 (95% credible interval 0.04, 0.97), 
barely different from the prior. We consider the estimates from the “3-4” model with 
secondary data as the best available from the study, due to their greater precision.  The 
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secondary data improves identification of the boundary between the CT- and CT+ distributions 
by eliminating the false positives in CT+ . This can be observed by comparing the posterior 
means and 95% credible intervals of the means and standard deviations of the CT- and CT+ 
distributions (Table 4). 
Sensitivity analyses reported in the Web Appendix 3 (Web Table 1, Web Table 2) showed that 
the main results were robust to reasonable changes in the priors, to distributional assumptions, 
and to the proportion of TFI cases in the secondary data. 
 
Discussion 
Estimates of the proportion of pelvic inflammatory disease, ectopic pregnancy, and infertility 
that can be attributed to Chlamydia are critical to motivating prevention and control programs 
for Chlamydia trachomatis (CT). A number of authors have attempted to derive estimates from 
serological case-control studies (13, 37), but these are confounded by other exposures that are 
likely to occur in women exposed to CT, which are also capable of causing reproductive damage 
(38). Previously, we attempted to derive estimates from a Dutch case-control study (39), taking 
account of the sensitivity and specificity of assays. That study was based on a form of the “2-3” 
mixture model, but utilized reported summary data which did not allow titer distributions to be 
modeled. However, according to its authors, recruitment to the original study was likely to be 
subject to selection biases (40), and the resulting estimate of 45%  (95% CrI: 28, 62 ) is likely to 
be an over-estimate. An estimate of 64% in Scotland was described as an upper bound (41). All 
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estimates of the PEF are, of course, specific to time and place. For public health purposes, 
estimates should be based on contemporary local data.   
This study shows how serum antibody titer distributions from case-control studies can be used 
to generate estimates of the PEF, based on finite mixture analysis. By attributing the causal 
mechanisms for TFI to differences between cases and controls in specific components of the 
titer distributions, rather than to differences in the overall prevalence of antibody, the mixture 
modeling approach reduces the extent to which PEF estimates are vulnerable to confounding, 
although it does not eliminate it, as discussed below.  
The demonstration that there are four component distributions might appear surprising, rather 
than the two-component +ves and –ves model that might have been expected. However, the 
source data used in this exercise (29)  has features that were apparent in earlier literature. 
Histograms suggesting two CT+ve “peaks” in control series have been published previously (11, 
12, 16).  Similarly, the very high titers seen in women with reproductive damage have also been 
well-documented for PID / salpingitis (10, 18), and TFI (11, 15, 16, 30, 31).  Our analyses suggest 
the fourth CT+++ component occurs only in TFI cases. We attempted to fit “4-4” models but 
were unable to achieve stable results. Possibly, evidence for a “4-4” model might be obtained 
with a larger sample, although our efforts to fit these models suggests that very few controls 
would be in the CT+++ group. 
Interpretation of the different antibody positive groups must be somewhat speculative. Given 
that salpingitis is a necessary condition for TFI (6, 32, 42), it seems reasonable to regard the 
CT+++ group, which is observed in cases only, as representing a causal mechanism linked to CT-
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related TFI. It is tempting to attribute this to a greater inflammatory response possibly due to a 
higher infectious load in those who develop TFI, as has been observed at the lower genital tract 
and in PID (43, 44). The 28.0% (6.9, 50.0) estimate of PEF based on the CT+++ distribution alone 
can be regarded as a lower bound because it ignores the excess CT++ observed in the cases. 
This excess was substantial: 29.4% of TFI cases were in the CT++ group, compared to the 6.5% 
of the controls (Table 4). We may speculate that the CT++  peak in the women without TFI 
might represent women who have had upper genital tract infection in whom inflammation has 
resolved, either following treatment or spontaneously, without causing tubal damage (6, 45), as 
well as women with recent lower genital tract infections or re-infections, as the decline in 
antibody over time is far less marked in second infections (46). The excess CT++ seen in cases 
could simply be due to increased exposure to CT in women whose TFI was in fact caused by 
other sexually transmitted infections or bacterial vaginosis. Bacterial vaginosis is associated 
with TFI (47) and with increased likelihood of CT infection and PID (48, 49). Sexual activity may 
also lead to ascending infection with common respiratory or enteric pathogens that colonize 
the genital tract, which are also capable of causing reproductive damage (50). 
Alternatively, women with TFI are more likely to have been exposed to  repeat CT infections, 
which is associated with both reproductive damage (44, 51) and with higher titers (46). For this 
reason we may regard the higher PEF estimate (43.0%, 95%CrI: 27.6, 57.5) as an upper bound 
as it ascribes the entire excess CT++ in cases to a causal mechanism rather than being partly or 
wholly the result of positive confounding. 
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The advantage of the mixture model estimates compared to the standard formula for PEF from 
case-control studies (52)  [ ( 1)] [ ( 1) 1]CT CTPEF OR ORπ π= − − +   is that they use the titer 
distribution as a marker of causal effect. This does not remove vulnerability to confounding, but 
it does limit it to a proportion of the CT++ distribution, subject of course to our interpretation of 
the distributions. We can contrast our estimates with those obtained from the standard 
formula for PEF from case control studies. Using the same WIF data with titres at 1:64 and 
below as negatives, the Odds Ratio for TFI from Table 1 is (380 x 358 / 76 x 193) = 9.27 (95% CI: 
6.9, 12.6). A population-based survey of the prevalence of Chlamydia antibody in 16-24 year old 
women in England, 2007-2010 (53)  generated an estimate of  22.9% (95% CrI: 20, 26) in 23-24 
year olds. This is most likely an underestimate of CTπ  in the case-control study because the 
mean age of women in the WIF data was 30. Applying the formula to these estimates gives a 
PEF of 65.4%, or 71.3% if CTπ  is 30%.  Both these estimates are upper bounds as they attribute 
all the excess prevalence to a causal effect; the lower bound is zero, representing the case 
where CT has no causal role in TFI but exposure to CT is common in those exposed to the true 
causes. 
Nevertheless, both higher and lower estimates generated by the mixture models should be 
viewed cautiously for two reasons. First, the modeling process was not all pre-planned: each 
successive model was data-driven, motivated by poor fit in the previous model. The formulae 
for the PEF estimates were also developed post hoc. Second, our findings are based on an 
analysis of data collected for a different purpose. Our results therefore need to be confirmed by 
a specifically planned study, using modern assays, many of which are far more specific (33). The 
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method could also be extended by testing samples for evidence of other pathogens capable of 
causing reproductive damage, including Mycoplasma genitalium (54),  Bacterial vaginosis (47) 
and possibly Neisseria gonorrhoeae (50).  The exercise could also be carried out on samples 
from women with PID and EP. If our results can be confirmed, finite mixture modeling may 
offer a way of quantifying the role of Chlamydia in reproductive damage, and form the basis for 
monitoring the impact of CT control programs in the population over time.  
<3712 words> 
  
19 
 
 
 Table 1.  Numbers of Samples From (a) TFI Cases and Controls Seen at Bristol Between 
1985-1995 and (b) From Secondary Anonymized Samples submitted at Bristol Public Health 
Laboratories during 2013 According to WIF Titer. 
Titer 
Group 
Category 
 
WIF titer 
(a) Case-control study (b) Secondary  data 
Controls  Cases Number  
Negative 
Percent 
negative 
Total 
1 <1:64 380 76 150 89.3 
 
168 
2 1:64 61 26 10     55.6 
 
18 
3 1:128 45 34 2 20.0 
 
10 
4 1:256 28 33 4 8.2 
 
49 
5 1:512 
 
20 48 0 0 39 
6 1:1024 
 
30 122 0 0 17 
7 1:2048 
 
9 69 - - - 
8 1:4096 
 
0 22 - - - 
9 >1:4096 0 4 - - - 
Totals  573 434 166  301 
Abbreviations: WIF, whole cell inclusion immune-fluorescence, Pgp-3, an immunogenic protein 
secreted by Chlamydia Trachomatis. 
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Table 2. Component Distributions in the Alternative Models and Estimators of Population Excess Fraction 
 
Model 
Controls Cases Estimator for Population Excess Fraction 
CT- CT+ CT++ CT- CT+ CT++a CT+++a 
 
“2-3” 
 
Y 
 
Y 
  
Y 
 
Y 
 
Y 
 
 
1,CTπ ++  
 
 
“3-3” 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
0,
1, 1, 1,
0, 0,
( ) CTCT CT CT
CT CT
π
π π π
π π
++
++ + ++
+ ++
 
− +   + 
 
 
“3-4” 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y 
 
Y  � 1,CTπ +++ , 0,1, 1, 1, 1,
0, 0,
( ) CTCT CT CT CT
CT CT
π
π π π π
π π
++
+++ ++ + ++
+ ++
 
+ − +   + 
 � b 
Abbreviations:  Model “2-3”,  the control samples are a mixture of two  distributions and cases are a mixture of three distributions; Model “3-3”, the 
control samples are a mixture of three  distributions and cases are a mixture of three  distributions; Model “3-4”,  the control samples are a mixture of 
three  distributions and cases are a mixture of four  distributions; CT-, Not infected Chlamydia Trachomatis ; CT+, Chlamydia Trachomatis previously 
infected but with no immune response; CT++, Chlamydia Trachomatis previously infected with immune response; CT+++, Chlamydia Trachomatis 
previously infected with exceptionally high levels of serum antibody. 
  
                                                          
a Latent group labels should be thought as mnemonics (see  Models in Methods section), 
b [,]: [Minimum, Maximum] 
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Abbreviations: TFI, tubal factor infertility; Model “2-3”, the control samples are a mixture of two distributions and cases are a mixture of three 
distributions; Model “3-3”,the control samples are a mixture of three distributions and cases are a mixture of three distributions;  Model “3-4”,  the 
control samples are a mixture of three distributions and cases are a mixture of four distribution 
 
                                                          
a Anonymised samples submitted for infertility investigations at the Bristol Public Health Laboratory during 2013 
b Women undergoing infertility investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, during 1985-1995. 
c Poorly fitting observations. 
Table 3. Observed and Predicted Frequency Counts of Each Titer, for Each Model, and Residual Deviance.  
 
Group 
 
Titers 
 
Observed 
Model “2-3” Model “3-3” Model “3-4” “3-4” with Secondary dataa 
Predicted Residual 
Deviance 
Predicted Residual 
Deviance 
Predicted Residual 
Deviance 
Predicted Residual 
Deviance 
 
 
 
 
Controlsb 
  
<1:64 380 378.1 1.0 378.0 1.0 378.3 1.0 377.8 1.0 
1:64 61 62.2 1.0 60.9 1.0 60.5 0.9 63.3 0.8 
1:128 45 42.2 0.7 44.9 0.5 45.4 0.5 42.9 0.5 
1:256 28 34.1 1.6 29.7 0.7 29.3 0.6 28.4 0.5 
1:512 20 26.6c 2.1c 21.4 0.5 19.6 0.6 20.7 0.5 
1:1024 30 17.0c 8.9c 21.3c 4.0c 28.8 1.0 28.8 1.0 
1:2048 9 8.4 0.4 13.1 1.8 10.3 0.8 10.1 0.8 
1:4096 0 3.2 6.4 3.3 6.6 0.7 1.4 0.8 1.6 
>1:4096 0 1.2 2.4 0.4 0.9 0.1 0.1 0.1 0.2 
  Total 573  25.4  17.0       7.1           6.8 
 
 
 
 
TFIb 
<1:64 76 77.4 1.0 76.6 1.0 76.4 1.0 76.1 1.0 
1:64 26 25.6 0.5 29.5 1.0 29.0 1.0 28.5 0.6 
1:128 34 29.8 1.1 30.5 1.0 31.8 0.7 32.2 0.6 
1:256 33 35.5 0.6 31.0 0.8 31.2 0.9 31.8 0.7 
1:512 48 57.9c 2.6c 59.7c 3.4c 52.7 1.4 51.8 1.2 
1:1024 122 105.1c 4.2c 108.1c 2.9c 118.4 1.1 118.5 1.1 
1:2048 69 80.0c 2.5c 77.1 1.6 69.3 0.7 69.7 0.8 
1:4096 22 20.0 1.2 19.3 1.1 20.1 1.0 20.5 0.9 
>1:4096 4 2.7 1.1 2.2 2.2 5.2 1.1 5.0 1.0 
 Total 434  14.7  15.1  8.8  7.8 
Grand Total   39.2  32.1  15.9  14.6 
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Table 4.  Posterior Summaries From the 4 Models:  Mean and Standard Deviation of the log Titers, and Percent in Each Component d in the 
Controls, 0dπ , and TFI Cases 1dπ  along with Estimates of the Population Excess Fraction. 
 Model “2-3” Model “3-3” Model “3-4” Model “3-4” with secondary dataa 
Group Means dµ  Mean 95% CrI    Mean    95% CrI Mean 95% CrI Mean 95% CrI 
𝝁𝝁𝟏𝟏 
𝝁𝝁𝟐𝟐 
𝝁𝝁𝟑𝟑 
𝝁𝝁𝟒𝟒 
-0.61 
  3.48 
5.84   
 
 -1.6, -0.00 
    2.3, 4.5 
 5.7, 6.0 
 
-1.09  
2.41  
5.72 
     
 -3.5,-0.01 
  1.3, 4.5 
   5.5, 5.9 
-1.15 
2.28  
5.60 
5.90      
-3.5, -0.03 
1.1, 3.4 
5.3, 5.8 
4.9, 7.0 
-0.70 
2.72  
5.59  
6.10          
-1.4, -0.2 
2.1, 3.4 
          5.3, 5.8 
5.2, 7.2 
Group Standard deviations dσ          
𝝈𝝈𝟏𝟏 
𝝈𝝈𝟐𝟐 
𝝈𝝈𝟑𝟑 
𝝈𝝈𝟒𝟒 
1.55 
1.87  
0.83   
0.8, 2.2 
1.5, 2.3 
0.6, 1.0 
1.54   
1.66    
0.90   
    0.51, 2.3 
    1.0, 2.2 
   0.60, 1.1 
1.48 
1.55  
0.56   
1.19    
0.48, 2.2 
1.0, 2.1 
0.3, 0.8 
0.7, 1.9 
1.60 
1.54 
0.56  
1.11        
1.2, 2.0 
1.2, 1.9 
0.3,0.8 
0.7, 1.8 
Mixing proportions: Controlsb         
𝝅𝝅𝟎𝟎𝟏𝟏 
𝝅𝝅𝟎𝟎𝟐𝟐 
𝝅𝝅𝟎𝟎𝟑𝟑 
74.5 
25.5    
57, 86 
14, 43 
67.9   
25.4 
6.65 
    45, 91 
    1.8, 48 
    2.6, 11 
66.5  
26.6  
6.92   
41, 87 
5.8, 52 
     3.7, 10 
74.0 
19.4 
6.54       
66, 83 
10, 28 
        3.3, 10 
Mixing proportions: Casesb         
𝝅𝝅𝟏𝟏𝟏𝟏 
𝝅𝝅𝟏𝟏𝟐𝟐 
𝝅𝝅𝟏𝟏𝟑𝟑 
𝝅𝝅𝟏𝟏𝟒𝟒 
16.8 
35.5 
47.8 
- 
6.3, 26 
    25, 47 
34, 58 
- 
12.7 
30.0 
57.3 
    1.3, 25 
    17, 44 
    35, 66 
- 
13.1  
26.9 
28.3  
31.7      
1.4, 24 
15, 40 
      8.7,50 
  8.7, 53 
16.4  26.3  29.4 28.0        
9.7, 22 
15, 37 
9.5, 50 
6.9, 50 
Population Excess Fraction   47.7  
 
34.2, 57.8 
 
35.9   -21.3, 52.7 
 
31.7c   
46.8d 
   8.7, 52.8 
 23.2, 64.1 
28.0a  
43.0b   
 6.9, 50.0 
27.6, 57.5 
Abbreviations: TFI, Tubal factor infertility; CrI, Credible interval; Model “2-3”, the control samples are a mixture of two distributions and cases are a 
mixture of three distributions; Model “3-3”, the control samples are a mixture of three distributions and cases are a mixture of three distributions; 
Model “3-4”, the control samples are a mixture of three distributions and cases are a mixture of four distributions.
                                                          
a Anonymised samples submitted for infertility investigations at the Bristol Public Health Laboratory during 2013 
b Women undergoing infertility investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, during 1985-1995. 
c Lower bound/minimum estimate for the population excess fraction 
d Upper bound/maximum estimate for the population excess fraction 
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Figure 1.  Fitted component distributions for controls (Panel A) and cases (Panel B) undergoing 
infertility investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, 
during 1985-1995, based on the model assuming two component distributions for cases and 
three for controlsa.  
 
Figure 2.  Fitted component distributions for controls (Panel A) and cases (Panel B) undergoing 
infertility investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, during 1985-
1995, based on the model assuming three component distributions for cases and three for 
controlsa.  
 
Figure 3.  Fitted component distributions for controls (Panel A) and cases (Panel B) Figure 1.  
Fitted component distributions for Controls (Panel A) and cases (Panel B) undergoing infertility 
investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, during 1985-
1995, based on the model assuming three component distributions for cases and four for 
controlsa. 
 
Figure 4.  Fitted component distributions for Controls (Panel A) and cases (Panel B) undergoing 
infertility investigations at the Reproductive Medicine Clinic, at St. Michael’s hospital, Bristol, 
during 1985-1995, based on the model assuming three component distributions for cases and 
four for controls and which also made use of secondary data on Anonymised samples submitted for 
infertility investigations at the Bristol Public Health Laboratory during 2013. 
                                                          
a The figure is drawn to a scale reflecting the mixing proportions, the predicted overall titer 
distribution (solid black line), and the observed data (dashed line histogram). The left-most 
histogram bar comprises titers below 1:64. This has been plotted to cover the area -5 to +1 on 
the log titer scale; its area corresponds to the proportion of data at these titers.   
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